Citation Impact 2023
Journal Impact Factor: 6.1
5-year Journal Impact Factor: 7.1
Source Normalized Impact per Paper (SNIP): 1.865
SCImago Journal Rank (SJR): 2.578
Speed 2023
Submission to first editorial decision (median days): 14
Submission to acceptance (median days): 129
Usage 2023
Downloads: 2,432,781
Altmetric mentions: 1,561
Articles
Page 105 of 108
-
Citation: Breast Cancer Research 2000 2(Suppl 1):S.36
-
Tissue microarrays for high-throughput profiling in molecular oncology
Citation: Breast Cancer Research 2000 2(Suppl 1):S.34 -
Blood assays for earlier detection of cancers
Citation: Breast Cancer Research 2000 2(Suppl 1):S.30 -
G1/S control and its deregulation in cancer
Citation: Breast Cancer Research 2000 2(Suppl 1):S.26 -
Role of the ATM gene in radiation sensitivity, relevance to breast cancer treatment
Citation: Breast Cancer Research 2000 2(Suppl 1):S.24 -
Cancer susceptibility in ATM heterozygotes: do two distinct carrier populations exist?
Citation: Breast Cancer Research 2000 2(Suppl 1):S.23 -
Lessons from TP53mutations in breast cancers: from carcinogen fingerprints to clinical correlates
Citation: Breast Cancer Research 2000 2(Suppl 1):S.21 -
Carcinoma-associated fibroblasts stimulate tumor progression of initiated human epithelium
Citation: Breast Cancer Research 2000 2(Suppl 1):S.19 -
Animal models of human tumor suppressor genes
Citation: Breast Cancer Research 2000 2(Suppl 1):S.17 -
Use of the anti HER-2/neu antibody Herceptin in the treatment of human breast cancer: biological rationale and clinical results
Citation: Breast Cancer Research 2000 2(Suppl 1):S.14 -
The EGF receptor family as targets for breast cancer therapy
Citation: Breast Cancer Research 2000 2(Suppl 1):S.13 -
Growth regulation and steroid hormone resistance in breast cancer
Citation: Breast Cancer Research 2000 2(Suppl 1):S.09 -
Transcript profiles and genotyping of cancer tissue
Citation: Breast Cancer Research 2000 2(Suppl 1):P8.10 -
Hypervariable area in the 5' flanking region of GSTP1, previously reported as a minisatellite repeat
Citation: Breast Cancer Research 2000 2(Suppl 1):P8.05 -
Exact quantification of gene amplification in archival tissue sections by laser-assisted microdissection and real-time PCR
Citation: Breast Cancer Research 2000 2(Suppl 1):P8.03 -
Promising method for DNA extraction from paraffin embedded archive material
Citation: Breast Cancer Research 2000 2(Suppl 1):P8.01 -
Expression profiling of BRCA1 associated breast tumors
Citation: Breast Cancer Research 2000 2(Suppl 1):P8.09 -
Genetic alterations in ductal carcinoma in situ and invasive carcinoma of the breast
Citation: Breast Cancer Research 2000 2(Suppl 1):P8.07 -
Does a polymorphism in the CYP17 gene predict mammographic density?
Citation: Breast Cancer Research 2000 2(Suppl 1):P7.03 -
Other cancers in BRCA1 and BRCA2 mutation carriers: implications for counselling and follow up
Citation: Breast Cancer Research 2000 2(Suppl 1):S.07 -
Molecular analyses of human breast cancer metastasis: genetic markers of progression
Citation: Breast Cancer Research 2000 2(Suppl 1):P7.01 -
Molecular characteristics of inherited breast tumors
Citation: Breast Cancer Research 2000 2(Suppl 1):S.06 -
Angiogenesis in breast cancer: establishing a link between angiogenesis and hormone regulation
Citation: Breast Cancer Research 2000 2(Suppl 1):P6.01 -
Negative regulation of p53 expression is an essential, rate-limiting function of Jun in the control of cell cycle progression
Citation: Breast Cancer Research 2000 2(Suppl 1):P5.04 -
Low frequency of p16 INK4a promoter methylation in mammary carcinomas as revealed by positive display of methylated sites
Citation: Breast Cancer Research 2000 2(Suppl 1):P5.02 -
Analysis of chromosome alterations and the E-cadherin and FHIT genes in lobular breast cancer
Citation: Breast Cancer Research 2000 2(Suppl 1):P4.13 -
Modulation of ATM gene expression in a murine mammary epithelial cell line
Citation: Breast Cancer Research 2000 2(Suppl 1):P4.10 -
Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients
Citation: Breast Cancer Research 2000 2(Suppl 1):P4.04 -
P53 mutations in breast and ovarian carcinomas from BRCA1 and 2 mutation carriers and noncarriers
Citation: Breast Cancer Research 2000 2(Suppl 1):P4.07 -
Genetic testing for BRCA1 and BRCA2 mutations - ready for implementation?
Citation: Breast Cancer Research 2000 2(Suppl 1):S.04 -
A detailed physical map of a region within human chromosome 16q22.1
Citation: Breast Cancer Research 2000 2(Suppl 1):P4.15 -
Screening breast cancer patients for Norwegian ATM mutations
Citation: Breast Cancer Research 2000 2(Suppl 1):P4.08 -
Role of the breast cancer susceptibility gene BRCA1 in radio-resistance
Citation: Breast Cancer Research 2000 2(Suppl 1):P4.01 -
Embryonic lethality in the Brca1-1700T mouse model suggests inhibition of p53-dependent pathways
Citation: Breast Cancer Research 2000 2(Suppl 1):P4.03 -
Anti-HER2 mAb plus calicheamicin immunoconjugate linked on liposomal vinorelbine induces ADCC and apoptosis in HER2-positive high grade DCIS
Citation: Breast Cancer Research 2000 2(Suppl 1):P3.05 -
The expression of the EGFR family members in breast carcinomas
Citation: Breast Cancer Research 2000 2(Suppl 1):P3.01 -
Factors modulating integrin Beta I expression on the breast cancer cell lines MCF-7 and MDA-MB-231
Citation: Breast Cancer Research 2000 2(Suppl 1):P3.06 -
IGFBP-7 expression in human breast cancer and association with proliferation and cell cycle aberrations
Citation: Breast Cancer Research 2000 2(Suppl 1):P3.02 -
The involvement of the MAPK signalling pathway in the adaptation of MCF-7 cells to long-term oestrogen deprivation
Citation: Breast Cancer Research 2000 2(Suppl 1):P2.05 -
Hairy and enhancer of split homolog-1 (HES-1) mediates the proliferative effect of Beta-estradiol on breast cancer cell lines
Citation: Breast Cancer Research 2000 2(Suppl 1):P2.03 -
Relative expression of progesterone receptors A and B in premalignant and invasive breast lesions
Citation: Breast Cancer Research 2000 2(Suppl 1):P2.01 -
Breast cancer in young women: prevalence of LOH at p53, BRCA1 and BRCA2
Citation: Breast Cancer Research 2000 2(Suppl 1):P1.04 -
Denaturing high-performance liquid chromatography (DHPLC) as a fast tool to screen a control population for the occurrence of unclassified variants (UV) in the BRCA1 gene
Citation: Breast Cancer Research 2000 2(Suppl 1):P1.01 -
X chromosome inactivation pattern in female patients with breast cancer
Citation: Breast Cancer Research 2000 2(Suppl 1):P1.10 -
Mammary-specific targeting of the murine BRCA2 breast cancer susceptibility gene in mice
Citation: Breast Cancer Research 2000 2(Suppl 1):P1.16 -
Mutational analysis of BRCA1 and BRCA2 genes in Spanish women with early-onset breast cancer
Citation: Breast Cancer Research 2000 2(Suppl 1):P1.07 -
Clinical and pathological characteristics in patients with BRCA1/2-mutation associated with breast cancer (BC) with a long clinical follow-up
Citation: Breast Cancer Research 2000 2(Suppl 1):P1.02 -
kConFab: a unique Australasian research initiative for familial breast cancer
Citation: Breast Cancer Research 2000 2(Suppl 1):P1.14 -
Germline BRCA2 and somatic P53alterations in male breast cancer
Citation: Breast Cancer Research 2000 2(Suppl 1):P1.12 -
BRCA1mutation analysis in breast and ovarian cancer families from Greece
Citation: Breast Cancer Research 2000 2(Suppl 1):P1.05